RSLS Quote, Financials, Valuation and Earnings

Electromed has a net margin of -68.98% compared to Reshape Lifesciences's net margin of 12.11%. Reshape Lifesciences's return on equity of -187.93% beat Electromed's return on equity of 15.91%.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 14598.41%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 60.94%. Given that Reshape Lifesciences has higher upside potential than Electromed, analysts believe Reshape Lifesciences is more attractive than Electromed.

Reshape Lifesciences has a beta of 1.592, which suggesting that the stock is 59.165% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than Electromed quarterly revenues of $16.3M. Reshape Lifesciences's net income of -$1.6M is lower than Electromed's net income of $2M. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Electromed's PE ratio is 30.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.03x versus 3.45x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -16.69%. Reshape Lifesciences's return on equity of -187.93% beat IRIDEX's return on equity of -157.91%.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 14598.41%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 83.49%. Given that Reshape Lifesciences has higher upside potential than IRIDEX, analysts believe Reshape Lifesciences is more attractive than IRIDEX.

Reshape Lifesciences has a beta of 1.592, which suggesting that the stock is 59.165% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than IRIDEX quarterly revenues of $11.6M. Reshape Lifesciences's net income of -$1.6M is higher than IRIDEX's net income of -$1.9M. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.03x versus 0.37x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -2.16%. Reshape Lifesciences's return on equity of -187.93% beat Myomo's return on equity of -48.64%.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 14598.41%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 106.01%. Given that Reshape Lifesciences has higher upside potential than Myomo, analysts believe Reshape Lifesciences is more attractive than Myomo.

Reshape Lifesciences has a beta of 1.592, which suggesting that the stock is 59.165% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than Myomo quarterly revenues of $12.1M. Reshape Lifesciences's net income of -$1.6M is lower than Myomo's net income of -$260.1K. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.03x versus 5.21x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -68.98% compared to Reshape Lifesciences's net margin of -118.53%. Reshape Lifesciences's return on equity of -187.93% beat Stereotaxis's return on equity of -139.2%.

Reshape Lifesciences has a consensus price target of --, signalling upside risk potential of 14598.41%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 126.13%. Given that Reshape Lifesciences has higher upside potential than Stereotaxis, analysts believe Reshape Lifesciences is more attractive than Stereotaxis.

Reshape Lifesciences has a beta of 1.592, which suggesting that the stock is 59.165% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Reshape Lifesciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reshape Lifesciences pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Reshape Lifesciences quarterly revenues are $2.3M, which are smaller than Stereotaxis quarterly revenues of $6.3M. Reshape Lifesciences's net income of -$1.6M is higher than Stereotaxis's net income of -$7.5M. Notably, Reshape Lifesciences's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reshape Lifesciences is 0.03x versus 6.30x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.